[1]
Wu Z, Qi B, Lin FF, Zhang L, He Q, Li FP, Wang H, Han YQ, Yin WJ. Characteristics of local extension based on tumor distribution in nasopharyngeal carcinoma and proposed clinical target volume delineation. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2023 Jun:183():109595. doi: 10.1016/j.radonc.2023.109595. Epub 2023 Mar 3
[PubMed PMID: 36870606]
Level 2 (mid-level) evidence
[2]
Bei JX, Su WH, Ng CC, Yu K, Chin YM, Lou PJ, Hsu WL, McKay JD, Chen CJ, Chang YS, Chen LZ, Chen MY, Cui Q, Feng FT, Feng QS, Guo YM, Jia WH, Khoo AS, Liu WS, Mo HY, Pua KC, Teo SH, Tse KP, Xia YF, Zhang H, Zhou GQ, Liu JJ, Zeng YX, Hildesheim A, International Nasopharyngeal Carcinoma (NPC) Genetics Working Group. A GWAS Meta-analysis and Replication Study Identifies a Novel Locus within CLPTM1L/TERT Associated with Nasopharyngeal Carcinoma in Individuals of Chinese Ancestry. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2016 Jan:25(1):188-192. doi: 10.1158/1055-9965.EPI-15-0144. Epub 2015 Nov 6
[PubMed PMID: 26545403]
Level 1 (high-level) evidence
[3]
Challapalli SD, Simpson MC, Adjei Boakye E, Walker RJ, Antisdel JL, Ward GM, Osazuwa-Peters N. Survival differences in nasopharyngeal carcinoma among racial and ethnic minority groups in the United States: A retrospective cohort study. Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery. 2019 Jan:44(1):14-20. doi: 10.1111/coa.13225. Epub 2018 Oct 3
[PubMed PMID: 30216675]
Level 2 (mid-level) evidence
[4]
Liao LJ, Hsu WL, Chen CJ, Chiu YL. Feature Reviews of the Molecular Mechanisms of Nasopharyngeal Carcinoma. Biomedicines. 2023 May 25:11(6):. doi: 10.3390/biomedicines11061528. Epub 2023 May 25
[PubMed PMID: 37371623]
[5]
Kamara S, Guo Y, Wen H, Liu Y, Liu L, Zheng M, Zhang J, Zhou L, Chen J, Zhu S, Zhang L. Novel Bifunctional Affibody Molecules with Specific Binding to Both EBV LMP1 and LMP2 for Targeted Therapy of Nasopharyngeal Carcinoma. International journal of molecular sciences. 2023 Jun 14:24(12):. doi: 10.3390/ijms241210126. Epub 2023 Jun 14
[PubMed PMID: 37373272]
[6]
Xiong Y, Yuan M, Liu Z, Huang J, Bi J, Pi G, Li Y, Li Y, He H, Verma V, Tian S, Han G. Long-Term Outcomes of Nasopharyngeal Carcinoma by Epstein-Barr Virus Status in the Chinese Population: A Multicenter Investigation. Journal of clinical medicine. 2023 Apr 20:12(8):. doi: 10.3390/jcm12083005. Epub 2023 Apr 20
[PubMed PMID: 37109338]
[7]
Benesch MGK, O'Brien SBL. Epidemiology of Undifferentiated Carcinomas. Cancers. 2022 Nov 25:14(23):. doi: 10.3390/cancers14235819. Epub 2022 Nov 25
[PubMed PMID: 36497299]
[8]
Geng X, Hao F, Han G, Zhang Y, Qin P. Dural and Multiple Brain Metastases From Basaloid Nasopharyngeal Carcinoma: Case Report and Literature Review. Frontiers in oncology. 2021:11():665652. doi: 10.3389/fonc.2021.665652. Epub 2021 Jul 14
[PubMed PMID: 34336659]
Level 2 (mid-level) evidence
[9]
Xu K, De Ravin E, Suresh N, Brody RM, Rajasekaran K. A comprehensive review and characterization of nasopharyngeal carcinoma clinical trials. World journal of otorhinolaryngology - head and neck surgery. 2023 Jun:9(2):174-182. doi: 10.1002/wjo2.80. Epub 2022 Sep 30
[PubMed PMID: 37383331]
[10]
Fu ZT, Guo XL, Zhang SW, Zeng HM, Sun KX, Chen WQ, He J. [Incidence and mortality of nasopharyngeal carcinoma in China, 2014]. Zhonghua zhong liu za zhi [Chinese journal of oncology]. 2018 Aug 23:40(8):566-571. doi: 10.3760/cma.j.issn.0253-3766.2018.08.002. Epub
[PubMed PMID: 30139025]
[11]
Adoga AA, Kokong DD, Ma'an ND, Silas OA, Dauda AM, Yaro JP, Mugu JG, Mgbachi CJ, Yabak CJ. The epidemiology, treatment, and determinants of outcome of primary head and neck cancers at the Jos University Teaching Hospital. South Asian journal of cancer. 2018 Jul-Sep:7(3):183-187. doi: 10.4103/sajc.sajc_15_18. Epub
[PubMed PMID: 30112335]
[12]
Blanchard P, Nguyen F, Moya-Plana A, Pignon JP, Even C, Bidault F, Temam S, Ruffier A, Tao Y. [New developments in the management of nasopharyngeal carcinoma]. Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique. 2018 Oct:22(6-7):492-495. doi: 10.1016/j.canrad.2018.06.003. Epub 2018 Aug 4
[PubMed PMID: 30087054]
[13]
Romdhoni AC, Rejeki PS, Guo HR, Milla C, Melbiarta RR, Visuddho V, Nugraha D. Risk Factors Associated with Nasopharyngeal Cancer Incidences in Indonesia: A Systematic Review and Meta-Analysis. Asian Pacific journal of cancer prevention : APJCP. 2023 Apr 1:24(4):1105-1111. doi: 10.31557/APJCP.2023.24.4.1105. Epub 2023 Apr 1
[PubMed PMID: 37116129]
Level 1 (high-level) evidence
[14]
Kondo S, Okuno Y, Murata T, Dochi H, Wakisaka N, Mizokami H, Moriyama-Kita M, Kobayashi E, Kano M, Komori T, Hirai N, Ueno T, Nakanishi Y, Endo K, Sugimoto H, Kimura H, Yoshizaki T. EBV genome variations enhance clinicopathological features of nasopharyngeal carcinoma in a non-endemic region. Cancer science. 2022 Jul:113(7):2446-2456. doi: 10.1111/cas.15381. Epub 2022 May 24
[PubMed PMID: 35485636]
[15]
Wee JT, Ha TC, Loong SL, Qian CN. Is nasopharyngeal cancer really a "Cantonese cancer"? Chinese journal of cancer. 2010 May:29(5):517-26
[PubMed PMID: 20426903]
Level 2 (mid-level) evidence
[16]
Li YC, Gao ZL, Liu KJ, Tian JY, Yang BY, Rahman ZU, Yang LQ, Zhang SH, Li CT, Achilli A, Semino O, Torroni A, Kong QP. Mitogenome evidence shows two radiation events and dispersals of matrilineal ancestry from northern coastal China to the Americas and Japan. Cell reports. 2023 May 30:42(5):112413. doi: 10.1016/j.celrep.2023.112413. Epub 2023 May 9
[PubMed PMID: 37164007]
[17]
Lian M. Salted fish and processed foods intake and nasopharyngeal carcinoma risk: a dose-response meta-analysis of observational studies. European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery. 2022 May:279(5):2501-2509. doi: 10.1007/s00405-021-07210-9. Epub 2022 Jan 30
[PubMed PMID: 35094122]
Level 1 (high-level) evidence
[18]
Kara B, Ertan K, Düzova M, Çağlayan AO, Köksal Y. Familial clustering of nasopharyngeal carcinoma in the family of an adolescent with nasopharyngeal carcinoma. The Turkish journal of pediatrics. 2022:64(6):1130-1135. doi: 10.24953/turkjped.2022.62. Epub
[PubMed PMID: 36583896]
[19]
Zhang WL, Zhang JB, Wang TM, Wu YX, He YQ, Xue WQ, Liao Y, Deng CM, Li DH, Wu ZY, Yang DW, Zheng XH, Li XZ, Zhou T, Zhang PF, Zhang SD, Hu YZ, Jia WH. Genomic landscape of Epstein-Barr virus in familial nasopharyngeal carcinoma. The Journal of general virology. 2022 Mar:103(3):. doi: 10.1099/jgv.0.001728. Epub
[PubMed PMID: 35349400]
[20]
Wang L, Song YL, Huang SM, Tao HX, Zhao YQ, Yan N, Xu DY. [The clinical significance of EBV DNA analysis in nasopharyngeal carcinoma screening]. Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology, head, and neck surgery. 2018 Feb:32(4):298-301. doi: 10.13201/j.issn.1001-1781.2018.04.014. Epub
[PubMed PMID: 29798510]
[21]
Kong FF, Pan GS, Du CR, Ni MS, Zhai RP, He XY, Shen CY, Lu XG, Hu CS, Ying HM. Prognostic value of circulating Epstein-Barr virus DNA level post-induction chemotherapy for patients with nasopharyngeal carcinoma: A recursive partitioning risk stratification analysis. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2023 Aug:185():109721. doi: 10.1016/j.radonc.2023.109721. Epub 2023 May 25
[PubMed PMID: 37244356]
[22]
Gihbid A, Benzeid R, Faouzi A, El Alami I, Tawfiq N, Benchakroun N, Bendahhou K, Benider A, Guensi A, Khaali W, Chaoui I, El Mzibri M, Cadi R, Khyatti M. The Dynamic Change in Plasma Epstein-Barr Virus DNA Load over a Long-Term Follow-Up Period Predicts Prognosis in Nasopharyngeal Carcinoma. Viruses. 2022 Dec 25:15(1):. doi: 10.3390/v15010066. Epub 2022 Dec 25
[PubMed PMID: 36680107]
[23]
Liu P, Xue XM, Zhang C, Zhou HW, Ding ZW, Jiang YK, Wang L, Shen WD, Yang SM, Wang FY. Prognostic factor analysis in patients with early-stage nasopharyngeal carcinoma in the USA. Future oncology (London, England). 2023 May:19(15):1063-1072. doi: 10.2217/fon-2022-0609. Epub 2023 Jun 7
[PubMed PMID: 37283023]
[24]
Chang ET, Adami HO. The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2006 Oct:15(10):1765-77
[PubMed PMID: 17035381]
[25]
Friborg J, Wohlfahrt J, Melbye M. Familial risk and clustering of nasopharyngeal carcinoma in Guangdong, China. Cancer. 2005 Jan 1:103(1):211; author reply 211-2
[PubMed PMID: 15540234]
[26]
Liao HM, Liu H, Chin PJ, Li B, Hung GC, Tsai S, Otim I, Legason ID, Ogwang MD, Reynolds SJ, Kerchan P, Tenge CN, Were PA, Kuremu RT, Wekesa WN, Masalu N, Kawira E, Ayers LW, Pfeiffer RM, Bhatia K, Goedert JJ, Lo SC, Mbulaiteye SM. Epstein-Barr Virus in Burkitt Lymphoma in Africa Reveals a Limited Set of Whole Genome and LMP-1 Sequence Patterns: Analysis of Archival Datasets and Field Samples From Uganda, Tanzania, and Kenya. Frontiers in oncology. 2022:12():812224. doi: 10.3389/fonc.2022.812224. Epub 2022 Mar 7
[PubMed PMID: 35340265]
[27]
Reffai A, Mesmoudi M, Derkaoui T, Ghailani Nourouti N, Barakat A, Sellal N, Mallick P, Bennani Mechita M. Epidemiological Profile and Clinicopathological, Therapeutic, and Prognostic Characteristics of Nasopharyngeal Carcinoma in Northern Morocco. Cancer control : journal of the Moffitt Cancer Center. 2021 Jan-Dec:28():10732748211050587. doi: 10.1177/10732748211050587. Epub
[PubMed PMID: 34664512]
Level 2 (mid-level) evidence
[28]
Bray F, Haugen M, Moger TA, Tretli S, Aalen OO, Grotmol T. Age-incidence curves of nasopharyngeal carcinoma worldwide: bimodality in low-risk populations and aetiologic implications. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2008 Sep:17(9):2356-65. doi: 10.1158/1055-9965.EPI-08-0461. Epub
[PubMed PMID: 18768504]
[29]
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. 2018 Nov:68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12
[PubMed PMID: 30207593]
[30]
Li WZ, Lv SH, Liu GY, Liang H, Xia WX, Xiang YQ. Age-dependent changes of gender disparities in nasopharyngeal carcinoma survival. Biology of sex differences. 2021 Jan 30:12(1):18. doi: 10.1186/s13293-021-00361-8. Epub 2021 Jan 30
[PubMed PMID: 33516267]
[31]
Liu F, Xie WB, Zhou LY, Liu YH, Fang WY, Yao KT. [Effect of A20 gene induced silencing on the biological behaviors of human nasopharyngeal carcinoma cell]. Zhonghua yi xue za zhi. 2018 Jun 26:98(24):1956-1961. doi: 10.3760/cma.j.issn.0376-2491.2018.24.013. Epub
[PubMed PMID: 29996290]
[32]
Xu M, Yao Y, Chen H, Zhang S, Cao SM, Zhang Z, Luo B, Liu Z, Li Z, Xiang T, He G, Feng QS, Chen LZ, Guo X, Jia WH, Chen MY, Zhang X, Xie SH, Peng R, Chang ET, Pedergnana V, Feng L, Bei JX, Xu RH, Zeng MS, Ye W, Adami HO, Lin X, Zhai W, Zeng YX, Liu J. Genome sequencing analysis identifies Epstein-Barr virus subtypes associated with high risk of nasopharyngeal carcinoma. Nature genetics. 2019 Jul:51(7):1131-1136. doi: 10.1038/s41588-019-0436-5. Epub 2019 Jun 17
[PubMed PMID: 31209392]
[33]
Su WH, Hildesheim A, Chang YS. Human leukocyte antigens and epstein-barr virus-associated nasopharyngeal carcinoma: old associations offer new clues into the role of immunity in infection-associated cancers. Frontiers in oncology. 2013 Dec 9:3():299. doi: 10.3389/fonc.2013.00299. Epub 2013 Dec 9
[PubMed PMID: 24367763]
[34]
Hau PM, Lung HL, Wu M, Tsang CM, Wong KL, Mak NK, Lo KW. Targeting Epstein-Barr Virus in Nasopharyngeal Carcinoma. Frontiers in oncology. 2020:10():600. doi: 10.3389/fonc.2020.00600. Epub 2020 May 14
[PubMed PMID: 32528868]
[35]
Tsao SW, Tsang CM, Lo KW. Epstein-Barr virus infection and nasopharyngeal carcinoma. Philosophical transactions of the Royal Society of London. Series B, Biological sciences. 2017 Oct 19:372(1732):. doi: 10.1098/rstb.2016.0270. Epub
[PubMed PMID: 28893937]
[36]
Tsao SW, Tsang CM, To KF, Lo KW. The role of Epstein-Barr virus in epithelial malignancies. The Journal of pathology. 2015 Jan:235(2):323-33. doi: 10.1002/path.4448. Epub
[PubMed PMID: 25251730]
[37]
Dawson CW, Port RJ, Young LS. The role of the EBV-encoded latent membrane proteins LMP1 and LMP2 in the pathogenesis of nasopharyngeal carcinoma (NPC). Seminars in cancer biology. 2012 Apr:22(2):144-53. doi: 10.1016/j.semcancer.2012.01.004. Epub 2012 Jan 12
[PubMed PMID: 22249143]
[38]
Raab-Traub N. Nasopharyngeal Carcinoma: An Evolving Role for the Epstein-Barr Virus. Current topics in microbiology and immunology. 2015:390(Pt 1):339-63. doi: 10.1007/978-3-319-22822-8_14. Epub
[PubMed PMID: 26424653]
[39]
Wang JH, Zhu H, Shang YF, Wang YJ, Li Y, Wang L, Huang SS, Lyu XQ. [Nasopharyngeal carcinoma with non-squamous immunophenotype: a clinicopathological analysis of 23 cases]. Zhonghua bing li xue za zhi = Chinese journal of pathology. 2022 Jun 8:51(6):500-505. doi: 10.3760/cma.j.cn112151-20211111-00816. Epub
[PubMed PMID: 35673720]
Level 3 (low-level) evidence
[40]
Kumari S, Pandey S, Verma M, Rana AK, Kumari S. Clinicopathological Challenges in Tumors of the Nasal Cavity and Paranasal Sinuses: Our Experience. Cureus. 2022 Sep:14(9):e29128. doi: 10.7759/cureus.29128. Epub 2022 Sep 13
[PubMed PMID: 36259025]
[41]
Zhai C, Yuan C, Sun J, Song W, Wang S, Lin L. Clinical and Histopathologic Analyses of Nasopharyngeal Hyalinizing Clear Cell Carcinoma: A Series of 26 Cases With Molecular Confirmation. The American journal of surgical pathology. 2023 Oct 1:47(10):1168-1175. doi: 10.1097/PAS.0000000000002092. Epub 2023 Jun 28
[PubMed PMID: 37377124]
Level 3 (low-level) evidence
[42]
Tay JK, Siow CH, Goh HL, Lim CM, Hsu PP, Chan SH, Loh KS. A comparison of EBV serology and serum cell-free DNA as screening tools for nasopharyngeal cancer: Results of the Singapore NPC screening cohort. International journal of cancer. 2020 May 15:146(10):2923-2931. doi: 10.1002/ijc.32774. Epub 2020 Jan 8
[PubMed PMID: 31705522]
[43]
Ito T, Majima H, Ozawa T, Maeda M, Iwamoto S, Hirayama M, Azuma E. An Unusual Presentation of Nasopharyngeal Carcinoma as Lemierre Syndrome. The American journal of case reports. 2019 Feb 28:20():263-267. doi: 10.12659/AJCR.913755. Epub 2019 Feb 28
[PubMed PMID: 30814483]
Level 3 (low-level) evidence
[44]
Weber AL, al-Arayedh S, Rashid A. Nasopharynx: clinical, pathologic, and radiologic assessment. Neuroimaging clinics of North America. 2003 Aug:13(3):465-83
[PubMed PMID: 14631685]
[45]
Goh J, Lim K. Imaging of nasopharyngeal carcinoma. Annals of the Academy of Medicine, Singapore. 2009 Sep:38(9):809-16
[PubMed PMID: 19816641]
[46]
King AD, Teo P, Lam WW, Leung SF, Metreweli C. Paranasopharyngeal space involvement in nasopharyngeal cancer: detection by CT and MRI. Clinical oncology (Royal College of Radiologists (Great Britain)). 2000:12(6):397-402
[PubMed PMID: 11202093]
[47]
King AD, Vlantis AC, Bhatia KS, Zee BC, Woo JK, Tse GM, Chan AT, Ahuja AT. Primary nasopharyngeal carcinoma: diagnostic accuracy of MR imaging versus that of endoscopy and endoscopic biopsy. Radiology. 2011 Feb:258(2):531-7. doi: 10.1148/radiol.10101241. Epub 2010 Dec 3
[PubMed PMID: 21131580]
[48]
Fong D, Bhatia KS, Yeung D, King AD. Diagnostic accuracy of diffusion-weighted MR imaging for nasopharyngeal carcinoma, head and neck lymphoma and squamous cell carcinoma at the primary site. Oral oncology. 2010 Aug:46(8):603-6. doi: 10.1016/j.oraloncology.2010.05.004. Epub 2010 Jul 8
[PubMed PMID: 20619723]
[49]
Yang SP, Li JF, Zhou P, Lian CL, Chen DX, Li ZJ, Wu SG. Biopsy of cervical lymph node does not impact the survival of nasopharyngeal carcinoma. Cancer medicine. 2021 Oct:10(19):6687-6696. doi: 10.1002/cam4.4204. Epub 2021 Aug 12
[PubMed PMID: 34382376]
[50]
Ye JX, Liang X, Wei J, Zhou J, Liao Y, Lu YL, Tang XQ, Wang AY, Tang Y. Compliance with National Guidelines on the Treatment of Stage II–IVB Nasopharyngeal Carcinoma in a Regional Cancer Center of Southern China. Asian Pacific journal of cancer prevention : APJCP. 2018 Jan 27:19(1):115-120
[PubMed PMID: 29373901]
[51]
Lee AW, Ng WT, Pan JJ, Poh SS, Ahn YC, AlHussain H, Corry J, Grau C, Grégoire V, Harrington KJ, Hu CS, Kwong DL, Langendijk JA, Le QT, Lee NY, Lin JC, Lu TX, Mendenhall WM, O'Sullivan B, Ozyar E, Peters LJ, Rosenthal DI, Soong YL, Tao Y, Yom SS, Wee JT. International guideline for the delineation of the clinical target volumes (CTV) for nasopharyngeal carcinoma. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2018 Jan:126(1):25-36. doi: 10.1016/j.radonc.2017.10.032. Epub 2017 Nov 15
[PubMed PMID: 29153464]
[52]
Tsang RK, Wei WI. Salvage surgery for nasopharyngeal cancer. World journal of otorhinolaryngology - head and neck surgery. 2015 Sep:1(1):34-43. doi: 10.1016/j.wjorl.2015.09.006. Epub 2015 Oct 24
[PubMed PMID: 29204538]
[53]
Tsang RK, Ng WT. Treatment of persistent/recurrent nodal disease in nasopharyngeal cancer. Current opinion in otolaryngology & head and neck surgery. 2021 Apr 1:29(2):86-92. doi: 10.1097/MOO.0000000000000687. Epub
[PubMed PMID: 33278136]
Level 3 (low-level) evidence
[54]
Lee AW, Ng WT, Pan JJ, Chiang CL, Poh SS, Choi HC, Ahn YC, AlHussain H, Corry J, Grau C, Grégoire V, Harrington KJ, Hu CS, Kwong DL, Langendijk JA, Le QT, Lee NY, Lin JC, Lu TX, Mendenhall WM, O'Sullivan B, Ozyar E, Peters LJ, Rosenthal DI, Sanguineti G, Soong YL, Tao Y, Yom SS, Wee JT. International Guideline on Dose Prioritization and Acceptance Criteria in Radiation Therapy Planning for Nasopharyngeal Carcinoma. International journal of radiation oncology, biology, physics. 2019 Nov 1:105(3):567-580. doi: 10.1016/j.ijrobp.2019.06.2540. Epub 2019 Jul 2
[PubMed PMID: 31276776]
[55]
Li AC, Zhang YY, Zhang C, Wang DS, Xu BH. Pathologic study of tumour extension for clinically localized unilateral nasopharyngeal carcinoma: Should the contralateral side be included in the clinical target volume? Journal of medical imaging and radiation oncology. 2018 May 28:():. doi: 10.1111/1754-9485.12741. Epub 2018 May 28
[PubMed PMID: 29808625]
[56]
Sun Y, Yu XL, Zhang GS, Liu YM, Tao CJ, Guo R, Tang LL, Zhang R, Guo Y, Ma J. Reduction of clinical target volume in patients with lateralized cancer of the nasopharynx and without contralateral lymph node metastasis receiving intensity-modulated radiotherapy. Head & neck. 2016 Apr:38 Suppl 1():E468-72. doi: 10.1002/hed.24020. Epub 2015 Jul 14
[PubMed PMID: 25677692]
[57]
Sanford NN, Lau J, Lam MB, Juliano AF, Adams JA, Goldberg SI, Lu HM, Lu YC, Liebsch NJ, Curtin HD, Chan AW. Individualization of Clinical Target Volume Delineation Based on Stepwise Spread of Nasopharyngeal Carcinoma: Outcome of More Than a Decade of Clinical Experience. International journal of radiation oncology, biology, physics. 2019 Mar 1:103(3):654-668. doi: 10.1016/j.ijrobp.2018.10.006. Epub 2018 Oct 15
[PubMed PMID: 30712708]
[58]
Ng WT, Chow JCH, Beitler JJ, Corry J, Mendenhall W, Lee AWM, Robbins KT, Nuyts S, Saba NF, Smee R, Stokes WA, Strojan P, Ferlito A. Current Radiotherapy Considerations for Nasopharyngeal Carcinoma. Cancers. 2022 Nov 24:14(23):. doi: 10.3390/cancers14235773. Epub 2022 Nov 24
[PubMed PMID: 36497254]
[59]
Ho FC, Tham IW, Earnest A, Lee KM, Lu JJ. Patterns of regional lymph node metastasis of nasopharyngeal carcinoma: a meta-analysis of clinical evidence. BMC cancer. 2012 Mar 21:12():98. doi: 10.1186/1471-2407-12-98. Epub 2012 Mar 21
[PubMed PMID: 22433671]
Level 1 (high-level) evidence
[60]
Wang G, Huang C, Yang K, Guo R, Qiu Y, Li W, Mao Y, Tang L, Ma J. Neck level Ib-sparing versus level Ib-irradiation in intensity-modulated radiotherapy for the treatment of nasopharyngeal carcinoma with high-risk factors: A propensity score-matched cohort study. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2022 Dec:177():205-213. doi: 10.1016/j.radonc.2022.11.005. Epub 2022 Nov 11
[PubMed PMID: 36375564]
Level 2 (mid-level) evidence
[61]
Kong F, Ying H, Du C, Huang S, Zhou J, Chen J, Sun L, Chen X, Hu C. Patterns of local-regional failure after primary intensity modulated radiotherapy for nasopharyngeal carcinoma. Radiation oncology (London, England). 2014 Feb 19:9():60. doi: 10.1186/1748-717X-9-60. Epub 2014 Feb 19
[PubMed PMID: 24552293]
[62]
Zhang S, Yang S, Xu P, Xu Y, Zhou G, Ou X, Wu R, Lan M, Fontanarosa D, Dowling J, Wang X, Lin S, Yi JL, Sun Y, Hu C, Lang J. Variations of Clinical Target Volume Delineation for Primary Site of Nasopharyngeal Cancer Among Five Centers in China. Frontiers in oncology. 2020:10():1572. doi: 10.3389/fonc.2020.01572. Epub 2020 Aug 20
[PubMed PMID: 32974193]
[63]
Buehrlen M, Zwaan CM, Granzen B, Lassay L, Deutz P, Vorwerk P, Staatz G, Gademann G, Christiansen H, Oldenburger F, Tamm M, Mertens R. Multimodal treatment, including interferon beta, of nasopharyngeal carcinoma in children and young adults: preliminary results from the prospective, multicenter study NPC-2003-GPOH/DCOG. Cancer. 2012 Oct 1:118(19):4892-900. doi: 10.1002/cncr.27395. Epub 2012 Feb 22
[PubMed PMID: 22359313]
Level 2 (mid-level) evidence
[64]
Young T, Thwaites D, Holloway L. Assessment of electron density effects on dose calculation and optimisation accuracy for nasopharynx, for MRI only treatment planning. Australasian physical & engineering sciences in medicine. 2018 Dec:41(4):811-820. doi: 10.1007/s13246-018-0675-2. Epub 2018 Aug 17
[PubMed PMID: 30120757]
[65]
Bouaouina N, Ouni S, Kanoun SB, Neffeti AB, Kermani W, Abdelkefi M. [Metastatic nasopharynx cancer at diagnosis: clinical and prognostic (study of 51 cases)]. The Pan African medical journal. 2018:29():155. doi: 10.11604/pamj.2018.29.155.11257. Epub 2018 Mar 15
[PubMed PMID: 30050619]
Level 3 (low-level) evidence
[66]
Gabani P, Barnes J, Lin AJ, Rudra S, Oppelt P, Adkins D, Rich JT, Zevallos JP, Daly MD, Gay HA, Thorstad WL. Induction chemotherapy in the treatment of nasopharyngeal carcinoma: Clinical outcomes and patterns of care. Cancer medicine. 2018 Aug:7(8):3592-3603. doi: 10.1002/cam4.1626. Epub 2018 Jul 14
[PubMed PMID: 30008178]
Level 2 (mid-level) evidence
[67]
Chen YP, Ismaila N, Chua MLK, Colevas AD, Haddad R, Huang SH, Wee JTS, Whitley AC, Yi JL, Yom SS, Chan ATC, Hu CS, Lang JY, Le QT, Lee AWM, Lee N, Lin JC, Ma B, Morgan TJ, Shah J, Sun Y, Ma J. Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2021 Mar 1:39(7):840-859. doi: 10.1200/JCO.20.03237. Epub 2021 Jan 6
[PubMed PMID: 33405943]
[68]
Al-Sarraf M, LeBlanc M, Giri PG, Fu KK, Cooper J, Vuong T, Forastiere AA, Adams G, Sakr WA, Schuller DE, Ensley JF. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1998 Apr:16(4):1310-7
[PubMed PMID: 9552031]
Level 1 (high-level) evidence
[69]
Chan AT, Leung SF, Ngan RK, Teo PM, Lau WH, Kwan WH, Hui EP, Yiu HY, Yeo W, Cheung FY, Yu KH, Chiu KW, Chan DT, Mok TS, Yau S, Yuen KT, Mo FK, Lai MM, Ma BB, Kam MK, Leung TW, Johnson PJ, Choi PH, Zee BC. Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma. Journal of the National Cancer Institute. 2005 Apr 6:97(7):536-9
[PubMed PMID: 15812080]
[70]
Wee J, Tan EH, Tai BC, Wong HB, Leong SS, Tan T, Chua ET, Yang E, Lee KM, Fong KW, Tan HS, Lee KS, Loong S, Sethi V, Chua EJ, Machin D. Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union against cancer stage III and IV nasopharyngeal cancer of the endemic variety. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Sep 20:23(27):6730-8
[PubMed PMID: 16170180]
Level 1 (high-level) evidence
[71]
Chen Y, Sun Y, Liang SB, Zong JF, Li WF, Chen M, Chen L, Mao YP, Tang LL, Guo Y, Lin AH, Liu MZ, Ma J. Progress report of a randomized trial comparing long-term survival and late toxicity of concurrent chemoradiotherapy with adjuvant chemotherapy versus radiotherapy alone in patients with stage III to IVB nasopharyngeal carcinoma from endemic regions of China. Cancer. 2013 Jun 15:119(12):2230-8. doi: 10.1002/cncr.28049. Epub 2013 Apr 10
[PubMed PMID: 23576020]
Level 1 (high-level) evidence
[72]
Lee AWM, Tung SY, Ng WT, Lee V, Ngan RKC, Choi HCW, Chan LLK, Siu LL, Ng AWY, Leung TW, Yiu HHY, O'Sullivan B, Chappell R. A multicenter, phase 3, randomized trial of concurrent chemoradiotherapy plus adjuvant chemotherapy versus radiotherapy alone in patients with regionally advanced nasopharyngeal carcinoma: 10-year outcomes for efficacy and toxicity. Cancer. 2017 Nov 1:123(21):4147-4157. doi: 10.1002/cncr.30850. Epub 2017 Jun 29
[PubMed PMID: 28662313]
Level 1 (high-level) evidence
[73]
Kwong DL, Sham JS, Au GK, Chua DT, Kwong PW, Cheng AC, Wu PM, Law MW, Kwok CC, Yau CC, Wan KY, Chan RT, Choy DD. Concurrent and adjuvant chemotherapy for nasopharyngeal carcinoma: a factorial study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2004 Jul 1:22(13):2643-53
[PubMed PMID: 15226332]
[74]
Hui EP, Ma BB, Leung SF, King AD, Mo F, Kam MK, Yu BK, Chiu SK, Kwan WH, Ho R, Chan I, Ahuja AT, Zee BC, Chan AT. Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Jan 10:27(2):242-9. doi: 10.1200/JCO.2008.18.1545. Epub 2008 Dec 8
[PubMed PMID: 19064973]
Level 1 (high-level) evidence
[75]
Lee AW, Ngan RK, Tung SY, Cheng A, Kwong DL, Lu TX, Chan AT, Chan LL, Yiu H, Ng WT, Wong F, Yuen KT, Yau S, Cheung FY, Chan OS, Choi H, Chappell R. Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrent-adjuvant to induction-concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fractionation in patients with locoregionally advanced nasopharyngeal carcinoma. Cancer. 2015 Apr 15:121(8):1328-38. doi: 10.1002/cncr.29208. Epub 2014 Dec 19
[PubMed PMID: 25529384]
[76]
Cao SM, Yang Q, Guo L, Mai HQ, Mo HY, Cao KJ, Qian CN, Zhao C, Xiang YQ, Zhang XP, Lin ZX, Li WX, Liu Q, Qiu F, Sun R, Chen QY, Huang PY, Luo DH, Hua YJ, Wu YS, Lv X, Wang L, Xia WX, Tang LQ, Ye YF, Chen MY, Guo X, Hong MH. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A phase III multicentre randomised controlled trial. European journal of cancer (Oxford, England : 1990). 2017 Apr:75():14-23. doi: 10.1016/j.ejca.2016.12.039. Epub 2017 Feb 16
[PubMed PMID: 28214653]
Level 1 (high-level) evidence
[77]
Yang Q, Cao SM, Guo L, Hua YJ, Huang PY, Zhang XL, Lin M, You R, Zou X, Liu YP, Xie YL, Wang ZQ, Mai HQ, Chen QY, Tang LQ, Mo HY, Cao KJ, Qian CN, Zhao C, Xiang YQ, Zhang XP, Lin ZX, Li WX, Liu Q, Li JB, Ling L, Guo X, Hong MH, Chen MY. Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: long-term results of a phase III multicentre randomised controlled trial. European journal of cancer (Oxford, England : 1990). 2019 Sep:119():87-96. doi: 10.1016/j.ejca.2019.07.007. Epub 2019 Aug 16
[PubMed PMID: 31425966]
Level 1 (high-level) evidence
[78]
Lee AWM, Ngan RKC, Ng WT, Tung SY, Cheng AAC, Kwong DLW, Lu TX, Chan ATC, Sze HCK, Yiu HHY, Wong FCS, Yuen KT, Chappell R, Choi HCW. NPC-0501 trial on the value of changing chemoradiotherapy sequence, replacing 5-fluorouracil with capecitabine, and altering fractionation for patients with advanced nasopharyngeal carcinoma. Cancer. 2020 Aug 15:126(16):3674-3688. doi: 10.1002/cncr.32972. Epub 2020 Jun 4
[PubMed PMID: 32497261]
[79]
Chen L, Hu CS, Chen XZ, Hu GQ, Cheng ZB, Sun Y, Li WX, Chen YY, Xie FY, Liang SB, Chen Y, Xu TT, Li B, Long GX, Wang SY, Zheng BM, Guo Y, Sun Y, Mao YP, Tang LL, Chen YM, Liu MZ, Ma J. Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial. The Lancet. Oncology. 2012 Feb:13(2):163-71. doi: 10.1016/S1470-2045(11)70320-5. Epub 2011 Dec 7
[PubMed PMID: 22154591]
Level 1 (high-level) evidence
[80]
Chitapanarux I, Kittichest R, Tungkasamit T, Asakit T, Chomprasert K, Chakrabandhu S, Onchan W, Traisathit P. Two-year outcome of concurrent chemoradiation with carboplatin with or without adjuvant carboplatin/fluorouracil in nasopharyngeal cancer: A multicenter randomized trial. Current problems in cancer. 2021 Feb:45(1):100620. doi: 10.1016/j.currproblcancer.2020.100620. Epub 2020 Jul 18
[PubMed PMID: 32713518]
Level 1 (high-level) evidence
[81]
Liu K, Wang J. Developing a nomogram model and prognostic analysis of nasopharyngeal squamous cell carcinoma patients: a population-based study. Journal of cancer research and clinical oncology. 2023 Oct:149(13):12165-12175. doi: 10.1007/s00432-023-05120-3. Epub 2023 Jul 10
[PubMed PMID: 37428250]
[82]
Peng WS, Xing X, Li YJ, Ding JH, Mo M, Xu TT, Zhou X, Hu CS. Prognostic nomograms for nasopharyngeal carcinoma with nodal features and potential indication for N staging system: Validation and comparison of seven N stage schemes. Oral oncology. 2023 Sep:144():106438. doi: 10.1016/j.oraloncology.2023.106438. Epub 2023 Jul 10
[PubMed PMID: 37437499]
Level 1 (high-level) evidence
[83]
Alami IE, Gihbid A, Charoute H, Khaali W, Brahim SM, Tawfiq N, Cadi R, Belghmi K, El Mzibri M, Khyatti M. Prognostic value of Epstein-Barr virus DNA load in nasopharyngeal carcinoma: a meta-analysis. The Pan African medical journal. 2022:41():6. doi: 10.11604/pamj.2022.41.6.28946. Epub 2022 Jan 3
[PubMed PMID: 35145598]
Level 1 (high-level) evidence
[84]
Wu CF, Lin L, Mao YP, Deng B, Lv JW, Zheng WH, Wen DW, Kou J, Chen FP, Yang XL, Xu SS, Ma J, Zhou GQ, Sun Y. Liquid biopsy posttreatment surveillance in endemic nasopharyngeal carcinoma: a cost-effective strategy to integrate circulating cell-free Epstein-Barr virus DNA. BMC medicine. 2021 Aug 26:19(1):193. doi: 10.1186/s12916-021-02076-4. Epub 2021 Aug 26
[PubMed PMID: 34433440]
[85]
Thamboo A, Tran KH, Ye AX, Shoucair I, Jabarin B, Prisman E, Garnis C. Surveillance tools for detection of recurrent nasopharyngeal carcinoma: An evidence-based review and recommendations. World journal of otorhinolaryngology - head and neck surgery. 2022 Sep:8(3):187-204. doi: 10.1016/j.wjorl.2020.12.002. Epub 2022 Apr 21
[PubMed PMID: 36159905]
[86]
Wei J, Pei S, Zhu X. Comparison of 18F-FDG PET/CT, MRI and SPECT in the diagnosis of local residual/recurrent nasopharyngeal carcinoma: A meta-analysis. Oral oncology. 2016 Jan:52():11-7. doi: 10.1016/j.oraloncology.2015.10.010. Epub 2015 Nov 4
[PubMed PMID: 26547126]
Level 1 (high-level) evidence
[87]
Ng SH, Chan SC, Yen TC, Liao CT, Chang JT, Ko SF, Wang HM, Lin CY, Chang KP, Lin YC. Comprehensive imaging of residual/ recurrent nasopharyngeal carcinoma using whole-body MRI at 3 T compared with FDG-PET-CT. European radiology. 2010 Sep:20(9):2229-40. doi: 10.1007/s00330-010-1784-9. Epub
[PubMed PMID: 20393714]
[88]
Liu T, Xu W, Yan WL, Ye M, Bai YR, Huang G. FDG-PET, CT, MRI for diagnosis of local residual or recurrent nasopharyngeal carcinoma, which one is the best? A systematic review. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2007 Dec:85(3):327-35
[PubMed PMID: 18037523]
Level 1 (high-level) evidence